IO Biotech, Inc. Stock: price and insider trades · United States

The lead asset is Cylembio® (imsapepimut and etimupepimut, adjuvanted), also known historically as IO102-IO103. This investigational vaccine is being evaluated primarily in combination with PD-1 inhibitors such as pembrolizumab (KEYTRUDA®) in advanced melanoma and in other solid-tumor settings. Beyond its lead program, IO Biotech is advancing additional preclinical candidates, including IO112, which targets arginase 1, and IO170, which targets TGF-β. That broader pipeline suggests a platform strategy rather than a single-asset story: IO Biotech is trying to build a family of therapeutic vaccines that address distinct immunosuppressive pathways.

In competitive terms, IO Biotech operates in a highly crowded oncology immunotherapy landscape dominated by large pharmaceutical groups and well-capitalized biotech peers. Its differentiation lies in the novelty of the T-win mechanism, the off-the-shelf nature of its vaccine candidates, and the potential to combine with existing checkpoint inhibitors rather than compete head-on with them. If the clinical signal holds, that could be meaningful in high-unmet-need indications such as melanoma, non-small cell lung cancer, and head and neck cancer.

Recent company highlights have centered on clinical execution and regulatory dialogue. In 2025, IO Biotech reported five-year clinical outcomes from an earlier phase 1/2 study, advanced enrollment and data generation across phase 2 programs, and disclosed pivotal phase 3 results for Cylembio in advanced melanoma. The company also referenced ongoing discussions with the FDA regarding the next development and filing path. For investors, IO Biotech remains a classic data-dependent biotech: the upside case is driven by clinical differentiation and regulatory progress, while the key risks are typical of development-stage oncology companies, including trial outcomes, financing needs, and commercialization uncertainty.